Dual mechanism inhibitors for the treatment of disease
View Patent ↗Provided are compounds that are inhibitors of both rho kinase and of a monoamine transporter (MAT) act to improve the disease state or condition. Further provided are compositions comprising the compounds. Further provided are methods for treating diseases or conditions, the methods comprising administering compounds according to the invention. One such disease may be glaucoma for which, among other beneficial effects, a marked reduction in intraocular pressure (IOP) may be achieved.
1. A compound according to Formula I:
and salts thereof,
wherein R 1 , R 2 , and R 3 are independently hydrogen, C 1 -C 4 alkyl, aryl, C 1 -C 4 alkyl aryl, C 1 -C 4 alkyl heteroaryl, C 1 -C 4 alkyl heterocyclyl, C 2 -C 4 alkenyl, C 2 -C 4 alkynyl, C 1 -C 4 carbonyl, C 1 -C 4 carbonylamino, C 1 -C 4 alkoxy, C 1 -C 4 sulfonyl, C 1 -C 4 sulfonylamino, C 1 -C 4 thioalkyl, C 1 -C 4 carboxyl, or form a ring with each other or with A;
wherein A is C 1 -C 4 alkyl, C 1 -C 4 alkyl aryl, C 1 -C 4 alkyl heteroaryl, or forms a ring structure with R 1 , R 2 or R 3 ;
wherein B is hydrogen, an aryl group, a heteroaryl group, a cycloalkyl group, a heterocycloalkyl group, C 1 -C 22 alkyl, C 1 -C 22 alkyl aryl, C 1 -C 22 alkyl heteroaryl, C 2 -C 22 alkenyl, C 2 -C 22 alkynyl, C 1 -C 22 carbonyl, C 1 -C 22 carbonylamino, C 1 -C 22 alkoxy, C 1 -C 22 sulfonyl, C 1 -C 22 sulfonylamino, C 1 -C 22 thioalkyl, or C 1 -C 22 carboxyl;
wherein X 1 , X 2 , and X 3 are, independently, hydrogen, hydroxyl, halogen, C 1 -C 4 alkyl, C 2 -C 4 alkenyl, C 2 -C 4 alkynyl, amino, aminocarbonyl, nitro, cyano, C 1 -C 4 carbonyl, C 1 -C 4 carbonylamino, C 1 -C 4 alkoxy, C 1 -C 4 sulfonyl, C 1 -C 4 sulfonylamino, C 1 -C 4 thioalkyl, or C 1 -C 4 carboxyl;
wherein the double circle
indicates an aromatic or heteroaromatic ring; and
wherein each Z is independently a bond, is C 1 -C 4 alkyl, heteroalkyl, or an O atom.
2. A compound according to claim 1 , wherein R 1 and R 2 are methyl or hydrogen, and wherein X 1 , X 2 , and X 3 are hydrogen.
3. A compound according to claim 1 , wherein B is an aliphatic carbonyl group.
4. A compound according to claim 1 , wherein B is a benzoic, pyridyl, naphthyl, benzothiophene, or thiazole carbonyl group.
5. A compound according to claim 1 , wherein Z is a bond or —CH 2 —.
6. A compound according to claim 1 , wherein X 1 , X 2 and X 3 are each hydrogen.
7. A compound according to claim 1 , wherein A is —CH 2 CH 2 —.
8. A compound according to claim 1 , wherein R 1 and R 2 are independently hydrogen or methyl.
9. A compound according to claim 1 , wherein R 3 is hydrogen or C 1 -C 4 alkyl.
10. A compound according to Formula III:
and salts and solvates thereof,
wherein R 1 and R 2 are independently hydrogen, C 1 -C 4 alkyl, C 1 -C 4 alkyl aryl, C 1 -C 4 alkyl heteroaryl, C 1 -C 4 alkyl heterocyclyl, or R 1 and R 2 together form a ring, either cycloalkyl or heterocycloalkyl;
wherein R 3 is hydrogen, C 1 -C 4 alkyl, C 1 -C 4 alkyl aryl, C 1 -C 4 alkyl heteroaryl, C 2 -C 4 alkenyl, C 2 -C 4 alkynyl, C 1 -C 4 carbonyl, C 1 -C 4 carbonylamino, C 1 -C 4 alkoxy, C 1 -C 4 sulfonyl, C 1 -C 4 sulfonylamino, C 1 -C 4 thioalkyl, or C 1 -C 4 carboxyl, or R 3 may from a ring with itself or R 1 or R 2 ;
wherein X 1 , X 2 , and X 3 are, independently, hydrogen, hydroxyl, halogen, C 1 -C 4 alkyl, C 2 -C 4 alkenyl, C 2 -C 4 alkynyl, amino, aminocarbonyl, nitro, cyano, C 1 -C 4 carbonyl, C 1 -C 4 carbonylamino, C 1 -C 4 alkoxy, C 1 -C 4 sulfonyl, C 1 -C 4 sulfonylamino, C 1 -C 4 thioalkyl, or C 1 -C 4 carboxyl;
wherein B is hydrogen, C 1 -C 18 alkyl, C 1 -C 18 alkyl aryl, C 1 -C 18 alkyl heteroaryl, C 1 -C 18 carbonyl, C 1 -C 18 carbonylamino, C 1 -C 18 sulfonyl, C 1 -C 18 sulfonylamino, or C 1 -C 18 carboxyl; and
wherein each Z is independently a bond, is C 1 -C 4 alkyl, heteroalkyl, or an O atom.
11. A compound according to Formula IV:
and salts thereof,
wherein R 1 and R 2 are independently hydrogen, C 1 -C 4 alkyl, C 1 -C 4 alkyl aryl, C 1 -C 4 alkyl heteroaryl, C 1 -C 4 alkyl heterocyclyl, or R 1 and R 2 together form a ring, either cycloalkyl or heterocyclyl;
wherein R 3 is a hydrogen, C 1 -C 4 alkyl, C 1 -C 4 alkyl aryl, C 1 -C 4 alkyl heteroaryl, C 2 -C 4 alkenyl, C 2 -C 4 alkynyl, C 1 -C 4 carbonyl, C 1 -C 4 carbonylamino, C 1 -C 4 alkoxy, C 1 -C 4 sulfonyl, C 1 -C 4 sulfonylamino, C 1 -C 4 thioalkyl, or C 1 -C 4 carboxyl;
wherein X 1 , X 2 , and X 3 are, independently, hydrogen, hydroxyl, halogen, C 1 -C 4 alkyl, C 2 -C 4 alkenyl, C 2 -C 4 alkynyl, amino, aminocarbonyl, nitro, cyano, C 1 -C 4 carbonyl, C 1 -C 4 carbonylamino, C 1 -C 4 alkoxy, C 1 -C 4 sulfonyl, C 1 -C 4 sulfonylamino, C 1 -C 4 thioalkyl, or C 1 -C 4 carboxyl;
wherein B is hydrogen, C 1 -C 18 alkyl, C 1 -C 18 alkyl aryl, C 1 -C 18 alkyl heteroaryl, C 1 -C 18 carbonyl, C 1 -C 18 carbonylamino, C 1 -C 18 sulfonyl, C 1 -C 18 sulfonylamino, or C 1 -C 18 carboxyl; and
wherein Z is a bond, C 1 -C 4 alkyl, heteroalkyl, or an O atom.
12. A compound according to claim 11 , wherein B is C 1 -C 2 alkyl aryl, C 2 -carbonyl, C 2 -carbonyl amino, C 2 -carboxyl, or C 2 -hydroxyl aryl.
13. A compound according to Formula V:
wherein Z is a bond or —CH 2 —; and
B is an aryl group, a heteroaryl group, a cycloalkyl group, a heterocycloalkyl group, C 1 -C 22 alkyl, C 1 -C 22 alkyl aryl, C 1 -C 22 alkyl heteroaryl, C 2 -C 22 alkenyl, C 2 -C 22 alkynyl, C 1 -C 22 carbonyl, C 1 -C 22 carbonylamino, C 1 -C 22 alkoxy, C 1 -C 22 sulfonyl, C 1 -C 22 sulfonylamino, C 1 -C 22 thioalkyl, or C 1 -C 22 carboxyl.
14. A compound selected from the group consisting of:
15. A compound according to Formula (VI):
wherein R 4 is methyl and n is 2.
16. 4-(3-Amino-1-(isoquinolino-6-ylamino)-1-oxopropan-2-yl)benzyl 2,4-dimethylbenzoate.
17. A pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier.
18. A method for treating a disease in a subject comprising:
administering to a subject an effective amount of a compound according to claim 1 ; wherein the disease comprises eye disease.
19. The method of claim 18 , wherein the eye disease comprises glaucoma or a neurodegenerative eye disease.
20. A method of modulating kinase activity comprising:
contacting a cell with a compound according to claim 1 in an amount effective to modulate kinase activity.
21. The method of claim 20 , wherein the cell is in a subject.
22. A method of reducing intraocular pressure comprising:
contacting a cell with a compound according to claim 1 in an amount effective to reduce intraocular pressure.
23. The method of claim 22 , wherein the cell is in a subject.
24. The compound according to claim 1 , wherein R 1 , R 2 , and R 3 are each hydrogen; A is CH 2 ; Z is bond; X 1 , X 2 , and X 3 are each hydrogen; and
is phenyl.
25. The compound of claim 24 , wherein B is methyl.
26. The compound of claim 24 , wherein B is C 1 -C 4 carbonyl.
27. The compound of claim 26 , wherein B is —C(O)-phenyl, —C(O)-dimethylphenyl, —C(O)—CH 2 -phenyl, —C(O)-cyclohexyl, or —C(O)-methylphenyl.
28. The compound according to claim 10 , wherein R 1 , R 2 , and R 3 are each hydrogen; Z is bond; and X 1 , X 2 , and X 3 are each hydrogen.
29. The compound of claim 28 , wherein B is C 1 -C 4 carbonyl.
30. The compound of claim 29 , wherein B is —C(O)-cyclopenyl, —C(O)-cyclohexyl, —C(O)-dimethylphenyl, —C(O)-buytl, —C(O)-phenyl, —C(O)-methoxyphenyl, —C(O)-adamantyl, —C(O)-propyl, or —C(O)—CH 2 -phenyl.
31. The compound according to claim 10 , wherein R 1 is CH 3 ; R 2 and R 3 are each hydrogen; Z is bond; X 1 , X 2 , and X 3 are each hydrogen; and B is C 1 -C 4 carbonyl.
32. The compound according to claim 1 , wherein the compound is selected from the following:
33. The compound according to claim 10 , wherein the compound is selected from the following: